full
border
#666666
https://www.arboretumvc.com/wp/wp-content/themes/zap-installable/
https://www.arboretumvc.com/wp/
#ffffff
style1

23
May

Strata Oncology, a precision oncology platform company, today announced the close of a $26 million USD Series B funding round. New investors Pfizer Ventures, Merck Global Health Innovation Fund, Deerfield Management and Renaissance Venture Capital Fund were joined by existing investors Arboretum Ventures and Baird Capital.
Link

Merck, Pfizer power tumor profiling firm Strata to $26M round – FierceBiotech Article
Link

0 Comments
18
May

AT&T and Aira extend their agreement as Aira made AT&T its global data provider as it begins to take the service to Australia, Canada and the U.K. This comes at a meaningful time. Today marks the 7th Global Accessibility Awareness Day (GAAD). The purpose of GAAD is to get everyone talking, thinking, and learning about digital access and inclusion for people with disabilities.
Link

0 Comments
30
Apr

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of NxThera. The company developed the Rezūm® system, a minimally invasive therapy (MIT) for patients with symptomatic benign prostatic hyperplasia (BPH). With the completion of the acquisition, NxThera will become part of the Boston Scientific Urology and Pelvic Health business.
Link

0 Comments
26
Apr

Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for patients with heart failure, today announced the company has closed a $39 million Series B financing. The round includes new investor, Australia-based Hostplus, venture debt from Oxford Finance LLC, as well as support from existing investors M. H. Carnegie & Co., Arboretum Ventures, Lumira Capital, LSP Health Economics Fund and Aperture Venture Partners.
Link

0 Comments
18
Apr

Swift Biosciences today announced the commercial release of its Accel-Amplicon Plus™ Cancer NGS Panels, a suite of nine tumor-specific and focused gene panels to facilitate targeted cancer sequencing. The Accel-Amplicon technology enables simultaneous detection of single nucleotide variants, copy number variants and small insertion and deletions to achieve comprehensive and exon-level hotspot coverage of clinically-relevant genes.

Link

0 Comments
scrollauto
Loading posts...
link_magnifier
#ffffff
on
loading
off